Zhaoke Ophthalmology Limited (6622.HK) HKSE
2.80
-0.03(-1.06%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.80
-0.03(-1.06%)
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
294
First IPO Date
April 29, 2021
| Name | Title | Pay | Year Born |
| Xiaoyi Li | Chief Executive Officer & Executive Chairman of the Board | 12.53M | 1963 |
| Xiangrong Dai | Chief Operating Officer & Executive Director | 2.21M | 1980 |
| Carol Liu | Group Head of Regulatory Affairs | 0 | 1984 |
| Yang Lei | Group General Counsel | 0 | 1981 |
| Lit Fui Lau | President & Chief Scientific Officer | 0 | 1963 |
| Mauro Bove | Senior Vice President of Corporate Development | 0 | 1955 |
| Suk Yan Yau | Vice President of Financial Dept. & Company Secretary | 0 | 1982 |
| Guohui Zhang | Senior Vice President of Manufacturing & Logistics | 0 | 1974 |
| Jiang Feng | Senior Vice President of Sales & Marketing | 0 | 1976 |
Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, and commercialization of therapies that address unmet medical needs in the People's Republic of China. It is developing various drugs that cover ophthalmic indications affecting the anterior and posterior segments, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.